Microbiome Drug Market Report: Trends, Forecast and Competitive Analysis to 2035

Microbiome Drug Market

The future of the global microbiome drug market looks promising with opportunities in the gastrointestinal disorder, autoimmune disorder, diabetes, and cancer markets. The global microbiome drug market is expected to reach an estimated $8620 million by 2035 from $741 million in 2027 with a CAGR of 35.9% from 2027 to 2035. The major drivers for this market are the increasing understanding of microbiomes role, the rising demand for personalized therapies, and the growing prevalence of chronic diseases.

• Lucintel forecasts that, within the type category, oral dosage form is expected to witness higher growth over the forecast period due to incorporation of microbiome-based therapies into existing oral drug formulations.
• Within the application category, gastrointestinal disorders is expected to witness the highest growth over the forecast period due to imbalances in the normal functions of the gut microbiome can lead to gastrointestinal disorders.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to greater investment in microbiome research, in addition to rising incidences of gastrointestinal disorders.

Emerging Trends in Microbiome Drug Market

Between 2025 and 2027, the microbiome drug market will become more established and regulatory pathways will become more clearly defined. Rebatyota and Vowst, the first two microbiome-based drugs to be approved by the FDA in May 2025, will set a regulatory framework and encourage the development of microbiome-based drugs in other therapeutic areas. The microbiome drug development focus will shift to value-add and establish repeatable business models, leading to the commercialization of a microbiome drug by 2027.

• Positive Regulatory Environment: The US FDA issued two microbiome-based drug approvals in May 2025, establishing a regulatory pathway for drugs for the treatment of recurrent Clostridium difficile infections and setting a precedent for the microbiome drug development. The FDA's actions are expected to facilitate the development of microbiome drugs in other therapeutic areas.
• Precision Microbiome RTTs: Narrowing the focus from the whole microbiome to individual components will continue. A growing number of microbiome-based drugs are focusing on patient stratification, allowing for the development of therapeutics that target specific patient populations and improving overall drug efficacy.
• Manufacturing Industrialization: Anaerobic processing, potency assays, and donor-independent cell banks are areas of investment for various commercial organizations. The products expected to be launched by 2023 are anticipated to play a significant role in overcoming the current challenges of consistency and variations in shelf life. During the next five to seven years, the ability to manufacture a product at scale will dictate which drug candidates graduate from the research lab to be commercially available.
• Beyond Infectious Diseases: It is expected that sponsor companies will expand their product development efforts to include conditions beyond the field of infectious diseases. The greater the company's understanding of the microbiome, the greater the likelihood that sponsor companies will explore various conditions.
• Economic Evidence and Convenience: Evidence suggests that in the near-term, greater emphasis will be placed on the endpoint of treating a patient vs. the means by which the treatment is administered. Thus, it is likely that products which provide durable improvements in patients, improve convenience, and reduce costs will be prioritized.

Changes in reimbursement policy will encourage manufacturers to develop products based on already established biology. In order to be successful, companies will need to have established manufacturing and supply chains. Firms that adopt a focus on improving health and wellness will be unsuccessful in the pharmaceutical market.

Recent Developments in the Microbiome Drug Market

Activity in the microbiome drug market picked up in 2025 and will continue through 2027, primarily due to further investment in the field. The first regulatory approvals for live biotherapeutic products are expected by 2027, and during this time, Lucintel expects advancements in microbiome drugs, such as consortia identification, oral delivery, and companion diagnostics, as well as process and manufacturing platforms.

• Late-stage Clinical Advancement: The first conditional marketing authorization (CMA) for a microbiome product was granted by the European Commission to Seres Therapeutics in February 2025 for Seres's Ser-109 product for the treatment of recurrent C. difficile infection. The CMA was based on positive Phase 2b data. Positive Phase 3 results for Ser-109, MaaT Pharma's microbiome drug candidate MaaT013, were also released in February 2025.
• Platform Acquisition: Mergers and acquisitions (M&A) involving microbiome platform companies also occurred in 2025. In April, Novome announced the $10 million sale of its engineered bacterial platform.
• Manufacturing Expansion: The need to produce larger doses of a biologic limited the number of clinical trials for microbiome products. Vedanta Biosciences announced in January 2025, that it was able to produce 1,000 or more doses of its drug candidate VE303.
• Hospital Partnerships: In 2025, hospital access programs for Ferring's Rebyota were expanded to over 500 sites. As the microbiome drug space unit, infection prevention drugs and first-generation evidence will be created for other indications.
• Regulatory Collaboration: Also in 2025, the FDA's acceptance of a biologics License Application for a microbiome drug with over 300 patients' data represents the first of its kind and set a regulatory precedent. This is expected to accelerate the development of similar drugs. Within the next 3-5 years, it is expected that larger biopharmaceutical companies will engage in collaborations for the microbiome space.

It is expected that over the next 5-10 years, the microbiome space will closely resemble the oncology drug space where late-stage collaborations and funding will lead to the first microbiome drugs to gain regulatory approval and subsequent adoption by health care systems.

Strategic Growth Opportunities in the Microbiome Drug Market

There are emerging opportunities for the commercialization of microbiome drugs as LBPs (live biotherapeutic products) become better defined and sequencing technologies improve. Starting in 2024, the market is expected to shift interest from the manufacturing of proof-of-concept products to the manufacturing of products directed against defined microbial consortia for various indications. Between 2024 and 2026, it is anticipated that the market will grow with products directed against microbiome-based consortia to address indications beyond C. difficile.

• Inflammatory Disease Application: According to Lucintel, the next growth opportunities in the microbiome market will be in the use of defined microbial consortia to address ulcerative colitis and Crohn's disease. Moreover, it has been reported that defined microbial consortia have potential to address Graft-versus-Host Disease.
• Oncology Combination Therapy: It is well known that the microbiome plays a critical role in the modulation of the immune system. Therefore, it is anticipated that the use of defined microbial consortia, in combination with immune checkpoint inhibitors, will improve the overall responsiveness to immune modulatory therapies. Furthermore, there is preliminary data to suggest that the use of antibiotics may influence the overall responsiveness to immune modulatory therapies. Therefore, it is anticipated that in the next 3 to 5 years, the microbiome will play a critical role in combination therapies in the field of oncology.
• Next-generation Products: Quality control and international distribution challenges result in a strong market preference for strain-level products. As of January 2025, several industry-leading programs reported completed panels of 30 or more strains. Premium prices will be justified for defined products of the microbiome. Definition and regulation will reduce variability in batch production.
• Expansion To Asia-Pacific: Increased antibiotic resistance and local development of biologics has created a market for microbiome therapies in Japan, South Korea, Australia and other regions. In 2025, the estimated market size of Japan's pharmaceutical industry was over $100 billion. Products will gain access to these markets quicker if local clinical studies are combined with strategic partnerships. Initial focus should be on markets with large numbers of patients suffering from recalcitrant infections.
• Microbiome Testing: The microbiome is useful to determine the likelihood of a favorable response to a given therapy. In addition, the microbiome can be sequenced to gauge the retention of a therapy or to measure other endpoints. In August 2025, microbiome assessment panels were commercially available to interrogate 100 or more bacterial specie. The use of microbiome testing for therapy can facilitate better patient outcomes, establish a consistent stream of revenue from a diagnostic service, and provide a justification for third party reimbursement.

Current trends suggest that in the near term, the largest source of revenue will be from the treatment of recalcitrant infections. However, therapy for other diseases with high unmet need, in conjunction with a strong microbiome diagnostics business, should provide robust, long term, international revenues.

Microbiome Drug Market Drivers and Challenges

Competing forces like changes in technology, consumer trends, the economy, and policies, as identified by Lucintel, facilitate and impede the introduction of microbiome drugs to the market. The report covers hurdles including the clinical evidence and long-term safety of microbiome drugs. The report covers the impacts of the above-mentioned factors on microbiome drug development.

The factors responsible for driving this market include:

• Increased Customer Interest: Rising customer interest in treatments for immune, metabolic, and infectious disorders as well as other gastrointestinal conditions has increased interest in microbiome drugs. Conventional therapies can result in broad-spectrum, systemic side effects and antimicrobial resistance. The increasing recognition of the role of microbiome and other bio-molecules in drug development strengthens and supports the case for personalized medicine. In April 2025, the World Health Organization (WHO) published a report stating that antibiotic resistance was one of the top 10 public health issues of primary concern, resulting in increased interest in microbiome-related research. During the next 3-5 years, additional microbiome-related drugs are expected to enter the market based on ongoing research and advocacy.
• Technology Advancements: New innovations in metagenomic sequencing, artificial intelligence (AI), and computer technologies make it easier to identify and analyse microbes that could be used in biological therapies. With the help of these technologies, researchers may eventually be able to better understand which microbes will be helpful and safe to use in a given patient. Real-time monitoring of microbial populations and ecosystems will let researchers tailor microbiome therapies to a patient's needs. Sequencing, along with other computational technologies, will improve the speed and efficiency of clinical research and help select patients most likely to benefit from a therapy. The following years will bring even more advancements in healthcare technologies. The quality of evidence and certainty in developing biologics will improve.
• Regulatory Changes: More established regulatory pathways to evaluate the safety of live and other biothreat products will foster research into biologics originating from the microbiome. Developers are benefiting from already-established regulatory pathways to evaluate products derived from microbiota. These pathways define requirements for various facets of product development, including patient safety and product potency. Over the last few years, increased attention by regulatory agencies on serious gastrointestinal infections has benefitted the microbiome research field. Regulatory agencies have promoted the use of novel approaches to address microbial resistance. Most agencies focus on establishing consistent methods to help assess the quality of biologics. These guidelines will benefit sponsors by reducing the time and cost of research and provide investors' confidence to fund microbiome research.
• Innovation in Product Development: Traditional FMT-based therapies are relatively simple. Other microbiome therapies, however, include defined microbial consortia and bacterial strains, bacteriophages, and metabolites, to name a few. These therapies, unlike FMT, are often engineered in a way to ensure a consistent and controlled dose. Further, many of these therapies may be easily dry-down stable and amenable to patient acceptance. Beyond the current focus of the microbiome field in gastrointestinal (GI) indications, product development is occurring for oncology and other field-defining conditions. There are ongoing clinical studies for microbiome-based therapies, and standardization in the field is rapidly progressing. In particular, the March 2025 studies evaluated products consisting of 10 or more microorganisms. In the next 3-5 years, continued product development is expected to expand the range of GI indications for which these therapies may be beneficial, and improve the commercial potential of these therapies.
• Advances in Manufacturing: There is ongoing research to improve the manufacturability of microbiome-based therapeutics. These advances, standardization in processes, and automation in fermentation are likely to reduce the cost to manufacture a dosage unit and meet regulatory requirements. The manufacturing of products consisting of microorganisms, particularly anaerobic organisms, may benefit from these advances. In August 2025, closed system processing was adopted to reduce the risk of contamination in the manufacturing of microbiome-based products. In the next 3-5 years, these and other process improvements are likely to improve the global availability and practicality of microbiome-based therapies.

The challenges facing this market include:

• Clinical Validation: Different individuals contain vastly different microbiome compositions. Many variables including diet, geography, other medications, age and the severity of the disease being treated, previous antibiotic use, and other factors can affect the efficacy of a microbiome-based treatment. Small clinical studies may show positive results, however larger studies may not be as promising due to a lack of control over the variables above. In February 2025, it was reported that microbiome clinical studies rely on the strict control of external variables such as diet and medication. It is expected that in the next three to five years, microbiome companies will not be able to adequately validate their products and treatments, thereby preventing clinical adoption and use.
• Manufacturing and Quality Control: Microbiome products are composed of living organisms and significant variations can occur during the production and storage of the product. Compared to standard small-molecule drugs, microbiome products pose greater challenges during production to ensure the purity and potency of the product. Quality and consistency during the production of microbiome products pose significant challenges and can adversely effect public safety. In October 2025, it was reported that the microbiome product industry was focused on improving analytical technology to verify the quality and consistency of microbiome products. In the next three to five years, the same challenges with product quality may increase the time it takes for regulatory authorities to approve microbiome products.
• Reimbursement and Safety Concerns: Payers may be reluctant to cover microbiome drugs due to the lack of clinical evidence on the drugs' benefits and costs compared to existing therapies. Healthcare professionals also have concerns about the introduction of unknown organisms, which could potentially cause infection or transmit genetically modified organisms to patients with compromised immunity. Uncertain awareness and complex procedure germane to microbiome drugs may complicate acceptance. As of May 2025, health economic evaluations were ongoing to assess the benefits of microbiome drugs, specifically to prevent frequent hospitalizations and the use of antibiotics. The author expects that in the next 3 to 5 years, the use of microbiome drugs would be determined by real world evidence, and if the drugs improve the overall economy of the healthcare system.

Microbiome drugs are expected to follow the trend of other novel cell and gene therapies and gain broader clinical acceptance in the next 3 to 5 years. Improvements in manufacturing and regulating processes would also facilitate the expansion of this therapeutic modality.

List of Microbiome Drug Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies microbiome drug market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the microbiome drug market companies profiled in this report include-

• Seres Therapeutics
• Assembly Biosciences
• Synthetic Biologics
• Finch Therapeutics
• PureTech
• Synlogic
• Enterome BioScience
• 4D Pharma
• Second Genome
• Ferring

Microbiome Drug Market by Segment

The study includes a forecast for the global microbiome drug market by type, application, and region.

Microbiome Drug Market by Type [Value ($M) from 2019 to 2035]:

• Oral Dosage Form
• Enteric Capsules

Microbiome Drug Market by Application [Value ($M) from 2019 to 2035]:

• Gastrointestinal Disorders
• Autoimmune Disorders
• Diabetes
• Cancer
• Others

Microbiome Drug Market by Region [Value ($M) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Microbiome Drug Market

Microbiome drug development has reached the stage where products can be manufactured at scale and commercial potential is beginning to be assessed. It is expected that between 2025 and 2027, there will be approvals, manufacturing investments and collaborations. In the opinion of Lucintel, the state of the art of microbiome drug development is largely governed by the pace of regulation.

• United States: Following FDA approvals of two microbiome products, companies have initiated development of products based on live biotic therapeutics and defined microbial consortia. Live biotherapeutic Products (LBPs) are defined by the FDA as biologics, and therefore require an advanced regulatory framework for their manufacture and clinical development. It is anticipated that the biologics framework will facilitate advancement of LBPs by alleviating uncertainty concerning their commercial manufacture.
• China: Several hospitals and research institutes in China are undertaking clinical research and developing GMP facilities for faecal microbiota transplantation (FMT) and defined microbiome therapies. In March 2025, the National Health Commission of China announced the establishment of 10 medical research centres to catalyse development of innovations in biopharmaceuticals including microbiome therapies.
• Germany: Biotech companies, universities, and hospital groups all conduct microbiome research in Germany. The country's large and established pharmaceutical industry, along with EU rules regarding manufacturing, further strengthen its position. German microbiome research is focused on clinical development, and in February 2025 the German Education Ministry granted several universities funding to pursue research collaborations.
• India: The microbiome research being conducted by the Indian pharmaceutical and research sectors is growing. Bioprocessing research is further supported by India's national biotechnology initiatives. In April 2025 the country's Biotechnology Department announced over 1,000 funded biotechnology projects. Low prices for research and development in the biotechnology sector, as well as improvements to local manufacturing in India, are the direct result of this public investment.
• Japan: University, hospital, and pharmaceutical sector research collaborations are supported by Japan's Public and Private Sector Joint Research Programs. AMED funded 22 of these programs in May 2025, including research aimed at microbiome-related gastrointestinal and immune disorders.

Features of the Global Microbiome Drug Market

• Market Size Estimates: microbiome drug market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: microbiome drug market size by type, application, and region in terms of value ($B).
• Regional Analysis: microbiome drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the microbiome drug market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the microbiome drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the microbiome drug market by type (oral dosage form and enteric capsules), application (gastrointestinal disorders, autoimmune disorders, diabetes, cancer, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?